GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Viaderma VDRM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$450,500

FY2015FY2024

Net income

−$3.9m

FY2015FY2024

Free cash flow

−$2.6m

FY2015FY2024

Shareholders' equity

−$3.7m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$450,500$600,498$540,648$514,007$11,468$10,395$45,973$44,691$251,981$191,777
Operating income−$869,200$185,270$245,190$328,120−$70,670−$337,760−$710,470−$593,400$127,450$93,750
Net income−$3.9m$4,097$590,674−$994,178−$431,673−$599,270−$3.0m−$1.5m−$121,806$27,121
Diluted earnings per share-0.000.000.00-0.00-0.00-0.00-0.01-0.00-0.000.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$3.6m$1.3m$713,979$275,021$123,033$69,225$56,415$426,560$386,504$175,858
Cash and short-term investments$11,900$10,243$10,068$11,561$10,135$9,904$10,020$13,082$9,843$18
Total liabilities$7.3m$1.2m$2.6m$2.7m$2.3m$3.1m$2.8m$1.5m$673,312$729,761
Debt$5.9m$322,939$415,181$415,181$588,598$769,602$718,535$408,358$306,629$288,251
Shareholders' equity−$3.7m$123,150−$1.8m−$2.4m−$2.2m−$3.0m−$2.7m−$1.1m−$286,808−$553,903
Shares outstanding1,234m1,234m984m984m862m1,234m339m442m220m1,234m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$2.6m$175−$1,492$1,425−$8,769−$15,116−$83,901−$167,361−$12,064−$11,189
Capital spending—−$5—−$4——————
Free cash flow−$2.6m$170−$1,492$1,421−$8,769−$15,116−$83,901−$167,361−$12,064−$11,189

Latest quarters

By quarter end

Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022
Revenue$150,189$150,131$150,490$150,065$150,203$150,105$150,125$135,648
Operating income−$294,453−$15,077$105,720$57,980$58,090$12,440$56,770−$73,450
Net income−$321,554−$33,178$87,615$39,782$39,891−$115,449$39,873−$82,427
Diluted earnings per share-0.00-0.000.000.000.00-0.000.00-0.00
Total assets$4.1m$1.3m$1.3m$1.3m$1.2m$1.1m$1.0m$713,979
Cash and short-term investments$1.5m$826,175$377,901$10,243$9,873$9,903$9,933$10,068
Debt$1.9m$322,939$322,939$322,939$322,939$322,939$382,939$415,181
Shareholders' equity−$144,397$177,158$210,765$123,150−$47,526−$87,418−$99,564−$1.8m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.3%112.5%13.2%
Operating income—20.8%-17.8%
Net income57.3%45.2%-5.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-65.1%-5.3%-24.4%-279.5%
Net margin-367.6%-202.7%-249.0%-586.6%

Valuation history

At each fiscal year end

FY2023
Price to earnings0.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return992%-21%47%-21%374%36%-44%-61%337%32%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 50-to-1 reverse split · 6 May 2014
  • 3-to-1 reverse split · 25 May 2010
  • 4-to-1 reverse split · 24 Jul 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.